Evidence map›Paper›PMID 41917040›Full record

ArticleNature communications2026

Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER

Jackson Liang, Christy Ong, Kareem Heslop, Jane Guan, Vasumathi Kameswaran, Bence Daniel, Minyi Shi, Yuxin Liang, Jennifer M Giltnane, Junko Aimi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jackson LiangDepartment of Translational Medicine, Genentech, South San Francisco, CA, USA. liang.jackson@gene.com.ORCID 0000-0003-3778-4614
Christy OngDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Kareem HeslopDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Jane GuanDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Vasumathi KameswaranDepartment of Proteomic and Genomic Technologies, Genentech, South San Francisco, CA, USA.ORCID 0000-0003-2552-6183
Bence DanielDepartment of Proteomic and Genomic Technologies, Genentech, South San Francisco, CA, USA.ORCID 0000-0002-2410-8767
Minyi ShiDepartment of Proteomic and Genomic Technologies, Genentech, South San Francisco, CA, USA.
Yuxin LiangDepartment of Proteomic and Genomic Technologies, Genentech, South San Francisco, CA, USA.
Jennifer M GiltnaneDepartment of Research Pathology, Genentech, South San Francisco, CA, USA.ORCID 0000-0002-8333-9995
Junko AimiDepartment of Translational Medicine, Genentech, South San Francisco, CA, USA.
Ching-Wei ChangDepartment of Biostatistics, Genentech, South San Francisco, CA, USA.
Mary R GatesDepartment of Early Clinical Development, Genentech, South San Francisco, CA, USA.
Jennifer Eng-WongDepartment of Early Clinical Development, Genentech, South San Francisco, CA, USA.
Pablo Perez-MorenoDepartment of Product Development, Genentech, South San Francisco, CA, USA.
Komal L JhaveriBreast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-0472-1254
Nicholas C TurnerRoyal Marsden Hospital and Institute of Cancer Research, London, UK.ORCID 0000-0001-8937-0873
Elgene LimSt Vincents Hospital, University of New South Wales and Garvan Institute, Sydney, NSW, Australia.ORCID 0000-0001-8065-8838
Ciara MetcalfeDepartment of Discovery Oncology, Genentech, South San Francisco, CA, USA.
Heather M MooreDepartment of Translational Medicine, Genentech, South San Francisco, CA, USA.

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Next-generation selective estrogen receptor-α (ERα) antagonist/degraders (SERDs) are being developed for ER-positive breast cancer (ER

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaAnimalsCell LineageCell Line, TumorFemaleForkhead Box Protein M1Gene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansNeoplasm MetastasisSignal TransductionERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaForkhead Box Protein M1FOXA1 protein, humanFOXM1 protein, humanHepatocyte Nuclear Factor 3-alpha

Identifiers

PMID41917040
PMCPMC13201648

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.